ATTAC-II: Newly-Diagnosed Glioblastoma - Clinical Trial
What is the Purpose of this Study?
We are doing this study to learn if the study vaccine is effective against a type of brain cancer called glioblastoma when it is given with stronger doses of normal chemotherapy.
Brain Cancer (newly diagnosed glioma)
Who Can Participate in the Study?
Adults 18 years old or older who have been newly diagnosed with glioblastoma.
What is Involved?
If you agree to be in this study:
-You will be randomly (like drawing numbers from a hat) assigned to one of three groups.
--Group 1 will receive the short preparation of the pp65 DC vaccine,
--Group 2 will receive the long preparation of the pp65 DC vaccine,
--Group 3 will receive a placebo that will look like and be given in the same way as the pp65 DC vaccine
- You will undergo a leukapheresis procedure in which blood is collected into a machine that removes white blood cells and then returns the remainder of the blood back to you. The white blood cells removed from the blood are used to make a study vaccine.
- After the leukapheresis, you will have standard treatment for your brain cancer (radiation therapy and chemotherapy) before you get the study vaccines. Vaccines are given as a shot in the leg.